Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...

Risk of death from all causes was similarly lower for patients on hemodialysis prescribed either allopurinol or febuxostat. Risk of CVD-related death was lower for those on allopurinol ...

MUNICH — A study evaluating the occurrence of CV, cerebrovascular and renal events in elderly patients with hyperuricemia showed that lowering serum uric acid levels with febuxostat had a ...

If you have a history of cardiovascular disease, you should only use febuxostat to treat your gout in two situations. The first is if you’re not able to take the gout drug allopurinol.

Credit: Getty Images. Major effects of febuxostat on renal outcome might be uric acid dependent, according to investigators. Beside reducing serum uric acid in patients with chronic kidney disease ...

Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with ...

Hyperuricemia is frequently observed among patient with chronic kidney disease. Febuxostat may offer superior renal-protective effects compared with allopurinol in patients with stage 3 chronic ...

kidney illustration Study of patients with CKD stage 3 and asymptomatic hyperuricemia showed that febuoxostat ameliorated the annual decline in eGFR vs placebo in those without proteinuria.

Febuxostat is a novel, non-purine, selective inhibitor of xanthine oxidase for hyperuricemia in patients with gout. It is the first promising substitute for allopurinol in 40 years. Various synthetic ...

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, and safety of febuxostat are reviewed. Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the ...